Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | PLK1 | P53350 | 3/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.58 |
| ▸ | THRA | P10827 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931328 | 0.91 | TRPV1 (0.64) | TRPV1NR1H4S1PR1KDM4EPLK1 | |
| SCHEMBL6927630 | 0.91 | TRPV1 (0.64) | TRPV1NR1H4S1PR1KDM4EPLK1 | |
| SCHEMBL12440862 | 0.87 | TRPV1 (0.69) | TRPV1KDM4EPLK1PLK3THRA | |
| SCHEMBL14088989 | 0.87 | NR1H4 (0.81) | TRPV1NR1H4KDM4ENPC1GALR3 | |
| SCHEMBL6931226 | 0.87 | TRPV1 (0.58) | TRPV1NR1H4S1PR1KDM4EPLK1 | |
| SCHEMBL6931223 | 0.87 | TRPV1 (0.58) | TRPV1NR1H4S1PR1KDM4EPLK1 | |
| SCHEMBL2831713 | 0.86 | TRPV1 (0.68) | TRPV1KDM4EPLK1PLK3THRA | |
| SCHEMBL15922369 | 0.86 | TRPV1 (0.68) | TRPV1KDM4EPLK1PLK3THRA | |
| SCHEMBL8756857 | 0.86 | TRPV1 (0.68) | TRPV1KDM4EPLK1PLK3THRA | |
| SCHEMBL8391488 | 0.86 | TRPV1 (0.68) | TRPV1KDM4EPLK1PLK3THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343306-B1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN PRESIDENT NAT CT NEUROLOGY & PSYCHIATRY (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-8034908-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2011-10-11 | — | — | US | disclosed |
| EP-2343306-A1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7732583-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20060074235-A1 | Glycolipids derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1619199-A1 | GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Daiichi Asubio Pharma Co., Ltd. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | SGMS1, UGCG, SGMS2 | TRPV1 3866/4885NR1H4 1702/4885S1PR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.